INTRODUCTION: @entity0 @entity1 have worse prognosis than normal weight @entity1 , but the level at which @entity28 is prognostically unfavorable is unclear. METHODS: This retrospective analysis was performed using data from the SUCCESS A trial, in which 3754 @entity1 with high-risk early @entity0 were randomized to @entity5948 - and @entity3907 -based chemotherapy with or without @entity136 . @entity1 were classified as underweight/normal weight (body mass index (BMI)   <   25.0), overweight (BMI 25.0-29.9), slightly @entity28 (BMI 30.0-34.9), moderately @entity28 (BMI 35.0-39.9) and severely @entity28 (BMI   >=    40.0), and the effect of BMI on disease-free survival (DFS) and @entity1349 ( @entity1349 ) was evaluated (median follow-up 65 months). In addition, subgroup analyses were conducted to assess the effect of BMI in luminal A-like, luminal B-like, @entity1722 ( @entity1 epidermal growth factor 2)-positive and @entity5 . RESULTS: Multivariate analyses revealed an independent prognostic effect of BMI on DFS (p   =   0.001) and @entity1349 (p   =   0.005). Compared with underweight/normal weight @entity1 , severely @entity28 @entity1 had worse DFS (hazard ratio (HR) 2.70, 95  % confidence interval (CI) 1.71-4.28, p   <   0.001) and @entity1349 (HR 2.79, 95  % CI 1.63-4.77, p   <   0.001), while moderately @entity28 and overweight @entity1 did not differ from underweight/normal weight @entity1 with regard to DFS or @entity1349 . Subgroup analyses showed a similar significant effect of BMI on DFS and @entity1349 in @entity1 with @entity0 ( @entity0 ), but not in @entity1 with other @entity5 subtypes. CONCLUSIONS: Severe @entity28 (BMI   >=    40) significantly worsens prognosis in early @entity0 @entity1 , particularly for @entity5 . TRIAL REGISTRATION: Clinicaltrials.gov NCT02181101 . Registered September 2005.

The influence of XXXX on survival in early, high-risk @entity0 : results from the randomized SUCCESS A trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'human'] @entity0 :: ('MESH:D001943', 'Disease') :: ['Obese breast cancer', 'breast cancer', 'triple-negative breast cancer', 'TNBC'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese, slightly obese', 'obese', 'obesity'] @entity1722 :: ('2064', 'Gene') :: ['HER2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'triple-negative tumors'] @entity5948 :: ('D018943', 'Chemical') :: ['anthracycline'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity28 :: (MESH:D009765,Disease) :: ['obesity']
